The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II randomized, open-label study of YM155 (sepantronium bromide) plus docetaxel versus docetaxel alone as first-line treatment for HER2 negative metastatic breast cancer.
Michael R. Clemens
Research Funding - Astellas Pharma
Anne Therese Keating
Employment or Leadership Position - Astellas Pharma
Oleg Gladkov
No relevant relationships to disclose
Fei Jie
Employment or Leadership Position - Astellas Pharma
Joyce Steinberg
Employment or Leadership Position - Astellas Pharma
Elaina M. Gartner
No relevant relationships to disclose
John Crown
Consultant or Advisory Role - Astellas Pharma
Honoraria - Sanofi
Vladimir Ivanovich Vladimirov
No relevant relationships to disclose